Cheese Intake and Hypercholesterolemia

Azienda Ospedaliera Brotzu42 enrolled

Overview

In this study the investigators aimed at verifying whether consumption of a sheep cheese, naturally enriched in alpha-lipoic acid (ALA), conjugated linoleic acid (CLA) and vaccenic acid (VA), would modify the plasma lipid and endocannabinoid profiles in mild hypercholesterolemic subjects.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Hypercholesterolemia

Interventions

CLA enriched cheeseDIETARY_SUPPLEMENT

This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 42 adult volunteers (19 male and 23 female) with diagnosed mild hypercholesterolemia (total cholesterol 220-290 mg/dL), * 30-60 years of age Exclusion Criteria: * Pregnant (or those planning to become pregnant during the study period) and lactating women were excluded; * also individuals with a self-reported history of diabetes, inflammatory bowel disease, pancreatitis, gallbladder or biliary disease in the past 12 months, and lactose intolerance before the screening visit. * In addition, those with a history of cancer (except non-melanoma skin cancer) in the 2 years before screening, or of any major trauma or surgical event within 3 months before screening, were not enrolled. * Volunteers with the following characteristics were also excluded: * total cholesterol ≥ 300 mg/dL, * serum triglycerides ≥ 250 mg/dL or ≤ 200 mg/dL, * HDL ≥ 70mg/dL, * BMI ≥ 30, or * uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg or * diastolic blood pressure ≥ 100 mm Hg) at screening.

Outcomes

Primary Outcomes

modification of LDL-cholesterol levels

Time frame: baseline and 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.